European CHMP recommends approval of lefamulin (Xenleta) for treatment of community-acquired pneumonia in adults

Lefamulin is a pleuromutilin antibacterial for systemic use which inhibits bacterial protein synthesis. Two studies (LEAP and LEAP 2) have reported non-inferiority to moxifloxacin +/- adjunctive linezolid. It will be available as a solution for infusion and 600 mg tablets.


European Medicines Agency